Consistently, treatment with HDAC inhibitors, such as MS275 and trichostatin A, in combination with targeted therapy leads to selective ablation of DTCs derived from lung cancer either in vivo or in vitro.44, 151. This evidence concerns the gene HDAC9 and lung cancer.